No Data
No Data
Renhe Pharmacy's Unit Gets Nod to Raise Specifications of Tadalafil Tablets
Are Renhe Pharmacy Co.,Ltd's (SZSE:000650) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
renhe pharmacy (000650.SZ): Tadalafil tablets (5mg, 10mg) obtained a pharmaceutical supplementary application approval.
Gelonghui, September 24th - Renhe Pharmacy (000650.SZ) announced that its wholly-owned subsidiary, Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd., recently received the "Drug Supplementary Application Approval Notice" of Tadalafil Tablets issued by the National Medical Products Administration. After review, the application meets the relevant requirements for drug registration, approving the addition of 10mg and 5mg specifications for the product, and issuing a drug approval number.
Renhe Pharmaceutical: 2024 Semi-Annual Report Summary
Renhe Pharmaceutical: 2024 Semi-Annual Report
Renhe Pharmacy (000650.SZ): The net income for the first half of the year was 0.337 billion yuan, a decrease of 5.43% year-on-year.
Renhe Pharmacy (000650.SZ) announced its interim report for the first half of 2024, with operating revenue of 2.364 billion yuan, a decrease of 11.84% year-on-year. Net income attributable to shareholders of the listed company was 0.337 billion yuan, a decrease of 5.43% year-on-year. Net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 0.252 billion yuan, a decrease of 19.29% year-on-year. Basic earnings per share were 0.2409 yuan.
No Data
No Data